Endocrine Abstracts

Introduction: Dopamine agonists have been reported to increase the risk of cardiac valve regurgitation in valve disease risks for 3 years treatment with cabergoline in patients with prolactinma. The aim of the study was to evaluate the frequency of cardiac valve diseases and regurgitation in patients with prolactinoma at the end of 3 years.

Subjects and method: Thirty-one patients with prolactinoma who had received cabergoline following 3 years were enrolled study. Two-dimensional and Doppler echocardiography were performed before treatment and after 3 years. All records were evaluated in all patients, retrospectively.

Results: Before treatment, 2 (2/31) patients had minimal mitral valve regurgitation and 1 (1/31) patient had minimal tricuspid insufficiency. Thickening of the mitral, tricuspid and aortic valves were not found before treatment. After 3 years, 1 (1/31) patients had moderate mitral valve regurgitation and 1 (1/31) patient had moderate tricuspid valve regurgitation. There were no statistically significantly differences of diameters of valves areas between two measurements (Table 1). Mean cumulative dose of cabergoline was 169.8±30.2 mg. Moderate valve regurgitation was not associated with cumulative dose of cabergoline (P=0.3).

Conclusions: Cabergoline therapy for 3 years was not associated with an increased risks of cardiac valve diseases and regurgitation in patients with prolactinoma.